EGFR and lung adenocarcinoma: The National Comprehensive Cancer Network (NCCN) guidelines now recommend routine testing for NTRK, ALK, ROS1, BRAF, and EGFR for all new cases of advanced lung adenocarcinoma for which we have therapies.